Overview
Anthony Paronneau advises clients on all aspects of corporate and business law, with a particular focus on pharmaceutical, medical device, biotech and healthcare industries.
Anthony has significant experience advising life sciences companies, private equity funds and venture capital firms on a number of merger and acquisition (M&A), and private equity transactions, including acquisitions, financing rounds, joint ventures and divestitures. He also regularly advises life sciences companies on collaborations, licensing and distribution arrangements.
Results
- Represented Vivet Therapeutics, a French biotech, on its exclusive option to be acquired by and its sale of a 15% ownership stake to Pfizer.
- Represented Servier on its acquisition of Symphogen.
- Represented Arterial Remodeling Technologies (ART), a French medtech developing an active bioabsorbable stent for the treatment of coronary disease, on its structured sale to the Japanese group Terumo Corporation.
- Represented the shareholders of Anaconda Pharma, a French biotech, on its structured sale to Biota.
- Advised Kuma Partners, LSP and Novo Ventures in a Series A fundraising of €67 million in Alizé Pharma III.
Recognitions
- The Best Lawyers in France, Biotechnology & Life Sciences, 2025
- Chambers Europe, France: Pharma/Life Sciences: Corporate, 2022-2024
- The Legal 500 EMEA, Leading Individual in France: Healthcare & Life Sciences, 2022 -2024
- IFLR1000, Corporate and M&A, 2022-2023
- Décideurs Juridiques, Capital Investments: Operational Risk, Excellent, 2020
- Décideurs Juridiques, Health, Pharma and Biotechnology: Digital Health, Forte Notoriété, 2019
- Décideurs Juridiques, Health, Pharma and Biotechnology: Regulatory, Excellent, 2019
- Décideurs Juridiques, Health, Pharma and Biotechnology: Joint Ventures and Corporate, Incontournable, 2019
- Décideurs Juridiques, Health, Pharma and Biotechnology: Capital Risk, Incontournable, 2019
